Who Paid My Doc
Stephen Scelsa
Neurology New York, NY
NPI 1770574980 CMS profile 79891
10 Union Sq E, New York, NY 10003
General payments
$0
Research payments
$0
Ownership & investment interest
$0
The CMS Open Payments record contains no reported payments to Stephen Scelsa of New York, NY.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
Prescribing to Medicare patients
Part D · data year 2024 · 37 drugsPart D claims
2,104
Drug cost
$4,756,068
Branded share of claims
23.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Radicava Ors Edaravone | Brand | 264 | $3,186,083 | |
| Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 | Brand | 38 | $602,223 | |
| Relyvrio Sod Phenylbutyrat/Taurursodiol | Brand | 36 | $433,816 | |
| Privigen Immun Glob G(Igg)/Pro/Iga 0-50 | Brand | 24 | $174,062 | |
| Gamunex-C Immune Globul G/Gly/Iga Avg 46 | Brand | 17 | $168,362 | |
| Teglutik Riluzole | Brand | 20 | $75,882 | |
| Nuedexta Dextromethorphan Hbr/Quinidine | Brand | 34 | $63,661 | |
| Riluzole | Generic | 190 | $16,252 | |
| Mycophenolate Mofetil | Generic | 71 | $7,975 | |
| Pyridostigmine Bromide | Generic | 112 | $7,540 |
The 10 drugs with the highest cost, of 37 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 26 billing codesPaid by Medicare
$56,277
Medicare patients
236
Services billed
840
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 72% | |
| Arthritis | 61% | |
| Diabetes | 42% | |
| Ischemic heart disease | 31% | |
| Depression | 25% | |
| Chronic kidney disease | 20% | |
| Cancer | 20% | |
| Osteoporosis | 17% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Other Neurology in New York
Related records
Neurology in New York
Practitioners in the same specialty and state, ranked by reported value.
All Neurology
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.